## Etoposide

### Indication
Ewing sarcoma of bone and articular cartilage of unspecified sites

### INN
Etoposide

### Medicine type
Chemical agent

### List type
Complementary (EML) (EMLc)

### Formulations
- **Parenteral > General injections > IV:** 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
- **Oral > Solid:** 100 mg capsule; 50 mg capsule

### EML status history
- First added in 2015 ([TRS 994](https://example.com/994))
- Changed in 2019 ([TRS 1021](https://example.com/1021))
- Changed in 2023 ([TRS 1049](https://example.com/1049))

### Sex
All

### Age
Also recommended for children

### Therapeutic alternatives
The recommendation is for this specific medicine

### Patent information
Patents have expired in most jurisdictions

### Tags
- Cancer

### Wikipedia
Etoposide

### DrugBank
Etoposide

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of etoposide (Powder for injection: 100 mg (as phosphate) in vial) to the EML and EMLc.

**Expert Committee report**